Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.002 | 0.0374 | 0.0058 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1047 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0174 | 1 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.2904 | 0.3976 |
Brugia malayi | MH2 domain containing protein | 0.0123 | 0.6794 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0071 | 0.3594 | 0.5045 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0123 | 0.6794 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0071 | 0.3594 | 0.3594 |
Schistosoma mansoni | hypothetical protein | 0.0174 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 0.3594 | 0.3594 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0337 | 0.0337 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0337 | 0.0337 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.2904 | 0.3976 |
Brugia malayi | RNA binding protein | 0.0071 | 0.3594 | 0.5045 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0337 | 0.0337 |
Loa Loa (eye worm) | TAR-binding protein | 0.0071 | 0.3594 | 0.5045 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1047 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 0.3594 | 0.3594 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0337 | 0.0337 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 0.3594 | 0.3594 |
Echinococcus granulosus | GPCR family 2 | 0.0019 | 0.0337 | 0.0337 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1047 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0337 | 0.0337 |
Brugia malayi | TAR-binding protein | 0.0071 | 0.3594 | 0.5045 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 0.3594 | 0.3594 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0337 | 0.0337 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1716 | 0.2136 |
Echinococcus multilocularis | tar DNA binding protein | 0.0071 | 0.3594 | 0.3594 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0337 | 0.0337 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.1047 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1716 | 0.1716 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.1047 | 0.1101 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0337 | 0.0337 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0071 | 0.3594 | 0.5045 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0123 | 0.6794 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.1047 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1716 | 0.2136 |
Schistosoma mansoni | tar DNA-binding protein | 0.0071 | 0.3594 | 0.3594 |
Brugia malayi | hypothetical protein | 0.003 | 0.1047 | 0.1101 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.2904 | 0.3976 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1047 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.1047 | 0.5 |
Echinococcus multilocularis | geminin | 0.0174 | 1 | 1 |
Echinococcus multilocularis | GPCR, family 2 | 0.0019 | 0.0337 | 0.0337 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0071 | 0.3594 | 0.5045 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.2904 | 0.3976 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.1047 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.